CAPR Stock — Capricor Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$9.89

Market cap

$576.16M

Price action

19 metrics

Price change (1W)

+20.7%

Price change (30D)

+138.3%

Price change (3M)

-63.4%

Price change (6M)

-61.3%

Price change (YTD)

-65.3%

Price change (1Y)

+59.4%

Trailing year

Price change (5Y)

+116.7%

52-week high

$35.34

52-week low

$3.85

Change from 52-week high

-71.7%

Change from 52-week low

+160.0%

Annualized volatility

394.4%

Beta

1.2

RSI (14D)

52.2

Price vs SMA 50

-29.8%

Price vs SMA 200

-57.1%

Avg volume (3M)

6.06M

Relative volume

1.0

Average dollar volume

$55.54M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

58.14M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

25.9×

reciprocal yield 3.9%

P / book

2.3

reciprocal yield 42.7%

FCF yield

-19.9%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-22.5%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-08-13

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$135.16M

Net income (TTM)

−$129.42M

Trailing 12 months

Diluted EPS (TTM)

$-2.45

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$0.05

Growth

11 metrics

Revenue growth YoY

-7.9%

Year over year

Net income growth YoY

—

Revenue (TTM)

$22.27M

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+26.7%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-52.6%

Return on assets

-35.1%

Debt / equity

—

Current ratio

7.3

EBITDA (TTM)

−$133.07M

Free cash flow (TTM)

−$114.90M

Quick ratio

7.3

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Cash & equivalents

$20.94M

Total assets

$368.74M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$104.00M

Capital expenditures (TTM)

$10.91M

R&D (TTM)

$99.73M

SG&A (TTM)

—

Stock compensation (TTM)

$9.77M

R&D / revenue

—

Stock compensation / revenue

43.8%

Ownership (13F)

3 metrics

13F filers

177

13F filer change QoQ

-4

Institutional ownership

79.0%

Short interest

3 metrics

Short interest

30.5%

Latest settlement · 1.6 days to cover

Days to cover

1.6d

Short-squeeze score

78 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$1.52M

Insider-sentiment score

25 / 100

Risk flags

1 metrics

Going concern

—

CAPR · Capricor Therapeutics, Inc.

CAPR metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search